News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Eleison Pharmaceuticals Announces Initiation of Phase 3 Trial of Glufosfamide for Second-line Treatment of Pancreatic Cancer


10/8/2013 9:29:17 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

ST. PETERSBURG Fla., Oct. 7, 2013 (GLOBE NEWSWIRE) -- Eleison Pharmaceuticals LLC, a specialty pharmaceutical company developing life-saving therapeutics for rare cancers, announced it has initiated a Phase III study of Glufosfamide for the second-line treatment of patients with pancreatic cancer.

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES